Isherwood / Augustin | Phenotypic Drug Discovery | Buch | 978-1-78801-876-0 | sack.de

Buch, Englisch, Band 77, 271 Seiten, Format (B × H): 155 mm x 236 mm, Gewicht: 590 g

Reihe: Drug Discovery

Isherwood / Augustin

Phenotypic Drug Discovery


Buch, Englisch, Band 77, 271 Seiten, Format (B × H): 155 mm x 236 mm, Gewicht: 590 g

Reihe: Drug Discovery

ISBN: 978-1-78801-876-0
Verlag: RSC Publishing

Phenotypic drug discovery has been highlighted in the past decade as an important strategy in the discovery of new medical entities. How many marketed drugs are derived from phenotypic screens? From the most recent examples, what were the factors enabling target identification and validation? This book answers these questions by elaborating on fundamental capabilities required for phenotypic drug discovery and using case studies to illustrate approaches and key success factors. Written and edited by experienced practitioners from both industry and academia, this publication will equip researchers with a thought-provoking guide to the application and future development of contemporary phenotypic drug discovery for clinical success.
Isherwood / Augustin Phenotypic Drug Discovery jetzt bestellen!

Autoren/Hrsg.

Isherwood, Beverley
Augustin, Angelique

Fachgebiete

Weitere Infos & Material

Phenotypic Drug Discovery: History, Evolution, Future; Development and Validation of Disease Assays for Phenotypic Screening; The Development and Use of Protein and Protein-affinity Libraries for Phenotypic Screening; CRISPR/Cas-based Functional Genomic Approaches to Phenotypic Screening; Contemporary Techniques for Target Deconvolution and Mode of Action Elucidation; Artificial Intelligence as an Enabler for Phenotypic Drug Discovery; Public–Private Partnerships to Advance Phenotypic Drug Discovery; Identification of a Novel Class
of Small Molecules for Spinal Muscular Atrophy Through High-throughput Phenotypic Screening; Antibody-based Phenotypic Screening – the Discovery of Oleclumab (MEDI9447); Use of Phenotypic Screening in Mice in the Development of a Novel Non-D2-Receptor-Targeting Drug for the Treatment of Schizophrenia; Phenotypic Screening for Drug Discovery in Tuberculosis; Why an In Vivo Screening Platform Covering Broad Therapeutic Spectrum is an Ideal Tool for Drug Repositioning: Illustrated by Discovery of a Novel Class of Insulin Sensitizers; Phenotypic Screen Leads to Identification of Novel Posttranscriptional Regulation Machinery for HBV

Holmberg-Schiavone, Lovisa
AstraZeneca, Sweden

Swinney, David
Institute for Rare and Neglected Diseases Drug Discovery, USA

Swalley, Susanne
Biogen, UK

Rust, Steve
Medimmune, UK

Davies, Rick
AstraZeneca, UK

Barrault, Denise
University of Edinburgh, UK

Ebner, Daniel
University of Oxford, UK

McDermott, Ultan
AstraZeneca, UK

Delorme, Vincent
Institut Pasteur Korea, Republic of Korea

Schirle, Markus
Novartis Institutes for Biomedical Research, Switzerland

Leahy, Emer
PsychoGenics, USA

Ihre Fragen, Wünsche oder Anmerkungen
Vorname*
Nachname*
Ihre E-Mail-Adresse*
Kundennr.
Ihre Nachricht*
Lediglich mit * gekennzeichnete Felder sind Pflichtfelder.
Wenn Sie die im Kontaktformular eingegebenen Daten durch Klick auf den nachfolgenden Button übersenden, erklären Sie sich damit einverstanden, dass wir Ihr Angaben für die Beantwortung Ihrer Anfrage verwenden. Selbstverständlich werden Ihre Daten vertraulich behandelt und nicht an Dritte weitergegeben. Sie können der Verwendung Ihrer Daten jederzeit widersprechen. Das Datenhandling bei Sack Fachmedien erklären wir Ihnen in unserer Datenschutzerklärung.